Ultragenyx Exceeds 2025 Revenue Guidance, Reports Strong Cash, and Highlights Key 2026 Pipeline Catalysts

summarizeSummary

Ultragenyx Pharmaceutical reported preliminary 2025 revenues exceeding guidance, a robust year-end cash position, and detailed multiple significant clinical and regulatory milestones anticipated for 2026.

check_boxKey Events

• Preliminary 2025 Revenue Exceeds Guidance

  Ultragenyx reported preliminary unaudited total revenue for fiscal year 2025 between $672 million and $674 million, surpassing the top end of its previous guidance range. Crysvita® revenue also exceeded guidance, while Dojolvi® revenue met the midpoint of its range.

• Strong Year-End Cash Position

  The company ended 2025 with approximately $735 million in cash and investments, providing a solid financial foundation for its operations and pipeline advancements.

• Key 2026 Regulatory Milestones Anticipated

  Ultragenyx expects a PDUFA date in Q3 2026 for DTX401 (GSDIa) and is on track for an early 2026 BLA resubmission for UX111 (MPS IIIA), representing two potential gene therapy approvals.

• Pivotal Phase 3 Data for Angelman Syndrome Expected

  Data from the fully enrolled, pivotal Phase 3 Aspire study of GTX-102 for Angelman syndrome is anticipated in the second half of 2026, a significant event for the pipeline.

auto_awesomeAnalysis

Ultragenyx Pharmaceutical reported preliminary 2025 revenues that surpassed its guidance, indicating strong commercial performance for its key products. The substantial year-end cash and investments position provides significant financial flexibility and runway for ongoing operations and pipeline development. The outlined 2026 clinical and regulatory catalysts, including two potential gene therapy approvals and pivotal Phase 3 data, are critical value drivers that could significantly de-risk the pipeline and fuel future growth, setting a positive outlook for the company's operational and clinical progress.